Targeted Silica Nanoparticles in Imaging Sentinel Lymph Nodes in Patients with Newly-Diagnosed and / or Recurrent Melanoma or Oral Cavity Squamous Cell Cancer
- Histologically confirmed diagnosis of melanoma at Memorial Sloan-Kettering Cancer Center (MSKCC)
- Have one of the following disease histories: * Newly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or oral cavity squamous cell carcinoma patients in whom sentinel lymph node (SLN) mapping is indicated ** Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas ** Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region ** Newly-diagnosed patients with previous excisional biopsy
- At the discretion of the physician or surgeon, normal baseline cardiac function based upon pre-operative evaluation
- At the discretion of the physician or surgeon, absolute neutrophil count (ANC) > 1000/mcl
- At the discretion of the physician or surgeon, platelets > 100,000/mcl
- At the discretion of the physician or surgeon, bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert’s)
- For melanoma patients, if patients have a history of malignancy other than melanoma and other skin cancers in the past five years, their inclusion is up to the discretion of the physician
- All patients of childbearing and child-creating age must be using an acceptable form of birth control
- Women who are pre-menopausal must have a negative serum pregnancy test
- Known pregnancy or breast-feeding
- Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the agent; this includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association classification III or IV heart disease
I. Determine the proportion of lymph nodes identified by 99mTc sulfur colloid that are positive by cRGDY-PEG-Cy5.5-C dot visualization.
II. Determine the proportion of patients in whom the surgical approach or extent of dissection was altered as a result of cRGDY-PEG-Cy5.5C dot visualization.
III. Determine whether the signal foci visualized optically correspond to lymph nodes or lymphatic channels.
IV. Monitor for adverse reactions to the non-radioactive particle probe as a safety endpoint.
I. Compare detection rates of cRGDY-PEG-Cy5.5-C dots and Tc99m sulfur colloid for pathology-positive sentinel lymph nodes (SLNs).
II. Correlate optical signal with tumor burden assessments.
III. Assess alpha-v integrin expression levels in primary and nodal tissue specimens derived from a subset of patients.
Up to 24 hours before or during surgery, patients receive fluorescent cRGDY PEG-Cy5.5 C dots intradermally (ID) or via intramucosal or periareolar injections.
After completion of study, patients are followed up at 2 weeks.
Trial Phase Phase I/II
Trial Type Diagnostic
Memorial Sloan Kettering Cancer Center
Hilda E Stambuk
- Primary ID 13-249
- Secondary IDs NCI-2016-01052
- Clinicaltrials.gov ID NCT02106598